Vascular Endothelial Growth Factor A in HIV and SARS-CoV-2 Infections

Medical News: The Role of VEGF A in Two Deadly Viral Infections
A recent study by researchers from the University of Pretoria in South Africa has shed light on the role of Vascular Endothelial Growth Factor A (VEGF-A) in the development and progression of both HIV and SARS-CoV-2 infections. VEGF-A is a protein responsible for forming new blood vessels and regulating vascular health, but its function can become a double-edged sword when dealing with these infections.


Vascular Endothelial Growth Factor A in HIV and SARS-CoV-2 Infections

This Medical News report explores how VEGF-A contributes to the severity of these viral infections, particularly its impact on the vascular system, inflammation, and coagulation issues. The study also highlights the possible therapeutic implications of targeting VEGF-A to mitigate complications associated with these diseases.
 
Understanding the Function of VEGF-A
VEGF-A is a key regulator of angiogenesis, the process through which new blood vessels form from existing ones. Under normal conditions, VEGF-A plays a crucial role in repairing tissues and ensuring proper blood flow. However, during infections like SARS-CoV-2 and HIV, its regulation is altered, leading to excessive inflammation and vascular complications.
 
In SARS-CoV-2 infection, the virus enters cells through the angiotensin-converting enzyme 2 (ACE2) receptor and neuropilin-1 (NRP-1). This interaction triggers an increase in VEGF-A levels, which, in turn, contributes to inflammation, vascular dysfunction, and coagulation abnormalities. The overproduction of VEGF-A can lead to leaky blood vessels, which exacerbates lung damage, contributing to conditions such as acute respiratory distress syndrome (ARDS).
 
Similarly, in HIV infection, the virus hijacks the body's natural angiogenesis mechanisms. The trans-activator of transcription (tat) protein in HIV mimics VEGF-A by binding to its receptor VEGFR-2. Additionally, HIV infection upregulates NRP-1, which enhances the interaction between VEGF-A and VEGFR-2, leading to increased angiogenesis. These changes can contribute to the chronic inflammation and vascular abnormalities commonly seen in people living with HIV, even when they are on antiretroviral therapy.
 
VEGF A in Co Infection of HIV and SARS-CoV-2
One of the most concerning findings of the study is the significantly higher VEGF-A levels in individuals co-infected with both HIV and SARS-CoV-2. This suggests that the combined effects of these infections on the vascular system are greater than either infection alone.
 
Researchers propose that the excess VEGF-A observed in these patients likely originates from activated immune cells rather than platelets. The study indicates that people living with HIV who are co-infected with SARS-CoV-2 experience less hypoxia compared to those without HIV. This suggests that VEGF-A’s association with hypoxia is altered in co-infected individuals, leading to distinct pathological mechanisms that require further investigation.
 
The Potential of Anti VEGF Therapies
Given VEGF-A’s role in exacerbating complications in both HIV and SARS-CoV-2 infections, researchers are now exploring the potential of anti-VEGF therapies. Some clinical trials have already indicated that blocking VEGF-A could help reduce inflammation, prevent vascular leakage, and improve overall outcomes in severe COVID-19 cases.
 
One promising approach involves using monoclonal antibodies such as bevacizumab, which has been approved for treating various cancers by targeting VEGF-A. Initial findings suggest that anti-VEGF therapies may decrease oxygen dependency in COVID-19 patients and reduce lung inflammation. However, experts caution that completely blocking VEGF-A could have negative effects, as it is also necessary for normal physiological processes, including wound healing and tissue repair.
 
To strike a balance, researchers recommend selectively inhibiting VEGFR-1 while preserving VEGFR-2 function. This targeted approach could prevent excessive angiogenesis and inflammation without completely disrupting VEGF-A’s beneficial roles. However, further clinical trials are needed to determine the safety and effectiveness of this strategy, particularly in individuals with HIV and those who are co-infected with SARS-CoV-2.
 
Future Research and Medical Implications
The study provides valuable insights into the complex role of VEGF-A in viral infections and raises several important questions for future research.
 
Understanding the precise mechanisms by which VEGF-A contributes to disease progression could lead to new treatment options that improve outcomes for patients with severe COVID-19 and those living with HIV.
 
Additionally, investigating how VEGF-A interacts with other inflammatory pathways could help identify novel therapeutic targets. The study suggests that therapies aimed at regulating VEGF-A expression and function might be beneficial not only in infectious diseases but also in other conditions characterized by excessive inflammation and vascular damage.
 
Conclusion
This research underscores the importance of VEGF-A in the pathogenesis of both HIV and SARS-CoV-2 infections. While VEGF-A plays a critical role in vascular health, its overexpression in these infections can lead to severe complications, including increased inflammation, blood clotting, and vascular leakage. The findings highlight the potential benefits of anti-VEGF therapies, but more research is needed to determine the best approach for targeting VEGF-A while preserving its essential functions.
 
Given the high burden of both HIV and COVID-19 in many parts of the world, these findings could have significant clinical implications. Future studies should focus on developing targeted therapies that modulate VEGF-A activity in a controlled manner to reduce disease severity and improve patient outcomes. As scientists continue to explore these avenues, the hope is that these insights will lead to more effective treatments that can mitigate the impact of these infections on the vascular system.
 
The study findings were published in the peer-reviewed journal: Frontiers in Cellular and Infection Microbiology.
https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2024.1458195/full
 
For the latest about Vascular Endothelial Growth Factor A, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/heart-attacks-scripps-institute-researchers-develop-small-molecule-tgp-377-to-trigger-protein-vegf-a-production-to-repair-post-heart-attack-cardiac-ti
 
https://www.thailandmedical.news/news/vascular-endothelial-growth-factors(vegfs)-can-prevent-blood-vessel-damage-caused-by-diabetes.
 
https://www.thailandmedical.news/articles/hiv-aids
 
Follow us on:
https://x.com/ThailandMedicaX
 
https://www.facebook.com/ThailandMedicalNews
 
https://bsky.app/profile/thailandmedical.bsky.social
 
https://gettr.com/user/thailandmedicalnews
 
https://www.tribel.com/thailandmedical/wall
 
and 33 other social media platforms